Aurrerapen terapeutikoak Parkinsonen gaixotasunean

Parkinson’s disease (PD) is a neurodegenerative disorder related to age which prevalence is increasing, estimating that the cases will double in the next 40 years. Currently, among drugs available, L-dopa continues being the most effective therapy, but does not stop or slow down the degeneration. Moreover, its efficacy diminishes over time of treatment while mayor side effects appear, as dyskinesia. This review provides an overview of new therapeutic advances to treat PD, including serotonergic and glutamatergic drugs, pharmacokinetic optimizing pharmaceutical preparations or transcranial magnetic stimulation.